Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

The MASK study group

Research output: Contribution to journalReviewResearchpeer-review

108 Downloads (Pure)

Abstract

Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors. Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018): MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.

Original languageEnglish
Article number16
JournalClinical and Translational Allergy
Volume9
Number of pages19
ISSN2045-7022
DOIs
Publication statusPublished - 11. Mar 2019

Fingerprint

Delivery of Health Care
Precision Medicine
Public Sector
Air Pollution
Health
Pharmacists
France
Comorbidity
Language
Physicians
Education

Keywords

  • App
  • Asthma
  • Care pathways
  • DG Santé
  • MASK
  • mHealth
  • Rhinitis

Cite this

@article{7180aa9a0f484eb4811993c52688c222,
title = "Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma",
abstract = "Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors. Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018): MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.",
keywords = "App, Asthma, Care pathways, DG Sant{\'e}, MASK, mHealth, Rhinitis",
author = "Bousquet, {P. J.} and A. Bedbrook and W. Czarlewski and Onorato, {G. L.} and S. Arnavielhe and D. Laune and E. Mathieu-Dupas and J. Fonseca and E. Costa and O. Louren{\cc}o and M. Morais-Almeida and A. Todo-Bom and M. Illario and E. Menditto and Canonica, {G. W.} and L. Cecchi and R. Monti and L. Napoli and Ventura, {M. T.} and {De Feo}, G. and Fokkens, {W. J.} and Chavannes, {N. H.} and S. Reitsma and Cruz, {A. A.} and {Da Silva}, J. and Serpa, {F. S.} and D. Larenas-Linnemann and Fuentes-Perez, {J. M.} and Huerta-Villalobos, {Y. R.} and D. Rivero-Yeverino and E. Rodriguez-Zagal and A. Valiulis and R. Dubakiene and R. Emuzyte and V. Kvedariene and I. Annesi-Maesano and H. Blain and P. Bonniaud and I. Bosse and Y. Dauvilliers and P. Devillier and Fontaine, {J. F.} and P{\'e}pin, {J. L.} and N. Pham-Thi and F. Portejoie and R. Picard and N. Roche and C. Bindslev-Jensen and E. Eller and S. Pedersen and {The MASK study group}",
year = "2019",
month = "3",
day = "11",
doi = "10.1186/s13601-019-0252-0",
language = "English",
volume = "9",
journal = "Clinical and Translational Allergy",
issn = "2045-7022",
publisher = "BioMed Central",

}

Guidance to 2018 good practice : ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. / The MASK study group.

In: Clinical and Translational Allergy, Vol. 9, 16, 11.03.2019.

Research output: Contribution to journalReviewResearchpeer-review

TY - JOUR

T1 - Guidance to 2018 good practice

T2 - ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

AU - Bousquet, P. J.

AU - Bedbrook, A.

AU - Czarlewski, W.

AU - Onorato, G. L.

AU - Arnavielhe, S.

AU - Laune, D.

AU - Mathieu-Dupas, E.

AU - Fonseca, J.

AU - Costa, E.

AU - Lourenço, O.

AU - Morais-Almeida, M.

AU - Todo-Bom, A.

AU - Illario, M.

AU - Menditto, E.

AU - Canonica, G. W.

AU - Cecchi, L.

AU - Monti, R.

AU - Napoli, L.

AU - Ventura, M. T.

AU - De Feo, G.

AU - Fokkens, W. J.

AU - Chavannes, N. H.

AU - Reitsma, S.

AU - Cruz, A. A.

AU - Da Silva, J.

AU - Serpa, F. S.

AU - Larenas-Linnemann, D.

AU - Fuentes-Perez, J. M.

AU - Huerta-Villalobos, Y. R.

AU - Rivero-Yeverino, D.

AU - Rodriguez-Zagal, E.

AU - Valiulis, A.

AU - Dubakiene, R.

AU - Emuzyte, R.

AU - Kvedariene, V.

AU - Annesi-Maesano, I.

AU - Blain, H.

AU - Bonniaud, P.

AU - Bosse, I.

AU - Dauvilliers, Y.

AU - Devillier, P.

AU - Fontaine, J. F.

AU - Pépin, J. L.

AU - Pham-Thi, N.

AU - Portejoie, F.

AU - Picard, R.

AU - Roche, N.

AU - Bindslev-Jensen, C.

AU - Eller, E.

AU - The MASK study group

A2 - Pedersen, S.

PY - 2019/3/11

Y1 - 2019/3/11

N2 - Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors. Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018): MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.

AB - Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors. Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018): MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.

KW - App

KW - Asthma

KW - Care pathways

KW - DG Santé

KW - MASK

KW - mHealth

KW - Rhinitis

U2 - 10.1186/s13601-019-0252-0

DO - 10.1186/s13601-019-0252-0

M3 - Review

C2 - 30911372

AN - SCOPUS:85062865821

VL - 9

JO - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

SN - 2045-7022

M1 - 16

ER -